Skip to content
GraphTheory.in
h-index
16

via OpenAlex

Citations
824

via OpenAlex

Publications
95

About

Rahul D. Jawarkar is an academic researcher affiliated with Devi Ahilya Vishwavidyalaya, focused on developing QSAR models and virtual screening techniques for identifying novel hits in various biological systems. His research spanned over 13 years (2013-2025), during which he published multiple papers on topics such as molecular docking, MD simulation, and MMGBSA studies, exploring pharmacophoric features of potential therapeutic leads.

Research areas

  • Chemistry
  • Stereochemistry
  • Medicine
  • Biology
  • Biochemistry

Publications (95)

Sorted by most cited.

  1. CoMSIA and POM analyses of anti-malarial activity of synthetic prodiginines

    2012

    View DOI
    41 cites
  2. RETRACTED: Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer’s disease

    2022

    View DOI
    29 cites
  3. Does tautomerism influence the outcome of QSAR modeling?

    2013

    View DOI
    28 cites
  4. Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual Screening, molecular Docking, MD simulation and MMGBSA approaches

    2022

    View DOI
    27 cites
  5. Molecular drug design, synthesis and pharmacophore site identification of spiroheterocyclic compounds: Trypanosoma crusi inhibiting studies

    2012

    View DOI
    26 cites
  6. Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals

    2022

    View DOI
    25 cites
  7. Design, synthesis of quinolinyl Schiff bases and azetidinones as enoyl ACP-reductase inhibitors

    2015

    View DOI
    25 cites
  8. Optimization of Antimalarial Activity of Synthetic Prodiginines: <scp>QSAR</scp>,<scp> GUSAR</scp>, and Co<scp>MFA</scp> analyses

    2012

    View DOI
    25 cites
  9. Challenges and measures during management of mounting biomedical waste in COVID-19 pandemic: an Indian approach

    2022

    View DOI
    24 cites
  10. QSAR and CoMFA studies of biphenyl analogs of the anti-tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo [2,1-b][1,3]oxazine (PA-824)

    2011

    View DOI
    20 cites
  11. Design, synthesis, QSAR modelling and molecular dynamic simulations of N-tosyl-indole hybrid thiosemicarbazones as competitive tyrosinase inhibitors

    2024

    View DOI
    19 cites
  12. Investigating the role of natural flavonoids in VEGFR inhibition: Molecular modelling and biological activity in A549 lung cancer cells

    2024

    View DOI
    19 cites
  13. k-NN, quantum mechanical and field similarity based analysis of xanthone derivatives as α-glucosidase inhibitors

    2012

    View DOI
    16 cites
  14. Synthesis, in vitro, and in silico studies of 7-fluorochromone based thiosemicarbazones as α-glucosidase inhibitors

    2025

    View DOI
    14 cites
  15. Computational POM and 3D-QSAR evaluation of experimental in vitro HIV-1-Integrase inhibition of amide-containing diketoacids

    2012

    View DOI
    14 cites
  16. POM as Efficient Tools to Predict and Improve Both Antibacterial and Antifungal Activity of Aryl Aldazines

    2011

    14 cites
  17. Synthesis of the chromone‐thiosemicarbazone scaffold as promising α‐glucosidase inhibitors: An in vitro and in silico approach toward antidiabetic drug design

    2024

    View DOI
    13 cites
  18. Identification of concealed structural alerts using QSTR modeling for Pseudokirchneriella subcapitata

    2021

    View DOI
    13 cites
  19. Molecular docking and quantitative structure–activity relationship (QSAR) analyses of indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors

    2013

    View DOI
    13 cites
  20. Natural compounds for oxidative stress and neuroprotection in schizophrenia: composition, mechanisms, and therapeutic potential

    2024

    View DOI
    10 cites
  21. 3D-QSAR Study on Coumarin Analogues as Potent Inhibitors of MAO-B using a COMFA Approach.

    2010

    10 cites
  22. COMFA Analysis and toxicity risk assessment of coumarin analogues as Mao-A Inhibitors: Attempting better insight in drug design

    2010

    10 cites
  23. Synthesis, Anti‐Alzheimer Evaluation and In Silico Study of 4‐Methoxyphenyl)Sulfonyl Indole Hybrid Thiosemicarbazones

    2025

    View DOI
    9 cites
  24. Design, Synthesis, In Vitro, and In Silico Studies of 5‐(Diethylamino)‐2‐Formylphenyl Naphthalene‐2‐Sulfonate Based Thiosemicarbazones as Potent Anti‐Alzheimer Agents

    2025

    View DOI
    9 cites
  25. Synthesis, <i>In-Silico</i>, <i>In Vitro</i> and DFT Assessments of Substituted Imidazopyridine Derivatives as Potential Antimalarials Targeting Hemoglobin Degradation Pathway

    2023

    View DOI
    9 cites
  26. POM analyses of antitrypanosomal activity of 2-iminobenzimidazoles: favorable and unfavorable parameters for drugs optimization

    2012

    View DOI
    9 cites
  27. Presuming the Probable Anti-inflammatory Mechanism of Ursolic Acid: a plant derived pentacyclic triterpenoid, using molecular docking

    2011

    9 cites
  28. <i>In vitro</i> and <i>in silico</i> analysis of synthesized <i>N</i>-benzyl indole-derived hydrazones as potential anti-triple negative breast cancer agents

    2025

    View DOI
    8 cites
  29. Synthesis, in silico studies and in vitro cytotoxicity evaluation of novel posaconazole derivative as a ALK TK inhibitor

    2024

    View DOI
    8 cites
  30. 3D-QSAR studies on xanthone derivatives to understand pharmacological activities as MAO inhibitors.

    2010

    8 cites
  31. Synthesis, human carbonic anhydrase I and II inhibition, and in silico studies of 2-ethoxy-6-formylphenyl [1,1′-biphenyl]-4-sulfonate derived thiosemicarbazones

    2025

    View DOI
    7 cites
  32. A decade review of analysis of essential oils from genus Artocarpus: Its phytochemistry and pharmacology

    2024

    View DOI
    7 cites
  33. Molecular docking, QSAR, and ADME studies of some pyrrolo[1, 2-a] benzimidazole-based quinones as novel topoisomerase 2 beta (TOP2β) inhibitors

    2024

    View DOI
    7 cites
  34. In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators

    2023

    View DOI
    7 cites
  35. A Review: Biological Importance of Mercapto Substituted 1,2,4-triazole Derivatives

    2012

    7 cites
  36. In-vitro and in-silico study to assess anti breast cancer potential of N-tosyl-indole based hydrazones

    2025

    View DOI
    6 cites
  37. Cheminformatics-driven prediction of BACE-1 inhibitors: Affinity and molecular mechanism exploration

    2024

    View DOI
    6 cites
  38. Hydrazide–Hydrazones as Potential Antitubercular Agents: An Overview of the Literature (1999–2023)

    2024

    View DOI
    6 cites
  39. Synthesis and antiproliferative evaluation of novel 3,5,8-trisubstituted coumarins against breast cancer

    2024

    View DOI
    6 cites
  40. Analyzing Oxygen Atom Distribution in FDA‐Approved Drugs to Enhance Drug Discovery Strategies

    2025

    View DOI
    5 cites
  41. Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors

    2024

    View DOI
    5 cites
  42. Role of phytochemicals as potential radioprotectants

    2022

    View DOI
    5 cites
  43. Exploring the use of herbal drugs and advanced supporting techniques for wound healing

    2022

    View DOI
    5 cites
  44. Exploring interactions of 2-Amino-6-arylsulfonylbenzonitrile derivatives as nonnucleoside reverse transcriptase inhibitors of HIV-1 using docking studies

    2011

    5 cites
  45. Design and synthesis of pyridazinone hybrid in PEG-400 as COX-1/COX-2 inhibitor and their antioxidant study

    2025

    View DOI
    4 cites
  46. Structural, dynamic behaviour, in-vitro and computational investigations of Schiff’s bases of 1,3-diphenyl urea derivatives against SARS-CoV-2 spike protein

    2024

    View DOI
    4 cites
  47. Mechanistic QSAR modeling derived virtual screening, drug repurposing, ADMET and <i>in</i> - <i>vitro</i> evaluation to identify anticancer lead as lysine-specific demethylase 5a inhibitor

    2024

    View DOI
    4 cites
  48. QSAR and docking based lead optimization of nitrogen heterocycles for enhanced prostaglandin EP2 receptor agonistic potency

    2024

    View DOI
    4 cites
  49. Docking Studies of few C-3 Substituted Azapteridines as Hepatitis C Virus RNA-Dependent RNA Polymerase inhibitors

    2011

    4 cites
  50. Targeting PI3K/AKT/mTOR signalling pathway in non-small-cell lung carcinoma: Exploring promising bioactive natural compounds as anti-cancer agents

    2024

    View DOI
    3 cites
  51. RETRACTED: Application of in-silico drug discovery techniques to discover a novel hit for target-specific inhibition of SARS-CoV-2 Mpro’s revealed allosteric binding with MAO-B receptor: A theoretical study to find a cure for post-covid neurological disorder

    2024

    View DOI
    3 cites
  52. Carbonylbis(hydrazine‐1‐carbothioamide) derivatives as a new class of α‐glucosidase inhibitors and their mechanistic insights via molecular docking and dynamic simulations

    2023

    View DOI
    3 cites
  53. Docking Analysis of Darunavir as HIV Protease Inhibitors

    2012

    3 cites
  54. Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 4‐Propylsulfonylpiperazines‐Based Thiosemicarbazones as Ecto‐5′‐Nucleotidase and NTPDase Inhibitors

    2025

    View DOI
    2 cites
  55. Synthesis, biological evaluation, and molecular modelling of substituted thiazolyl thiourea derivatives: A new class of prolyl oligopeptidase inhibitors

    2024

    View DOI
    2 cites
  56. Unveiling dynamics of nitrogen content and selected nitrogen heterocycles in thrombin inhibitors: a <i>ceteris paribus</i> approach

    2024

    View DOI
    2 cites
  57. QSAR modelling to predict structural features of certain sulfonamide as Urokinase-type Plasminogen Activator inhibitors

    2024

    View DOI
    2 cites
  58. Comparative Account of Diverse Regulatory Guidelines for Storage and Transportation of Pharmaceuticals

    2015

    2 cites
  59. Impact of tautomery of 3-(4H-1,2,4-triazol-3-ylthio)-N-phenylpropanamide on the COX-1 inhibitory mechanism

    2012

    View DOI
    2 cites
  60. From in-silico QSAR modeling to in-vitro MTT assay: experimental validation of novel uPAR leads for triple-negative breast cancer (TNBC) and skin cancer

    2026

    View DOI
    1 cites
  61. Application of chemoinformatics and molecular simulations in lead optimization targeting A549 cell proliferation for lung cancer therapy

    2025

    View DOI
    1 cites
  62. Identification of pharmacophore synergism for optimization of estrogen receptor beta binders for hormone dependent forms of breast cancer

    2025

    View DOI
    1 cites
  63. Synergizing GA-XGBoost and QSAR modeling: Breaking down activity cliffs in HDAC1 inhibitors

    Journal of Molecular Graphics and Modelling2025journal article

    View DOI
    1 cites
  64. Cheminformatics approaches to predict the bioactivity and to discover the pharmacophoric traits crucial to block NF-κB

    2024

    View DOI
    1 cites
  65. Analysis of malathion in biological samples using thin layer chromatography

    2013

    1 cites
  66. Characterization, evaluation of products synthesized in the interaction of 4- (N-substituted)-3-pyridyl- 5- mercapto-S-triazole with secondary amines

    2011

    1 cites
  67. Exploring the mechanism of Zanamivir as Anti-AIV agent by Molecular Docking and receptor based electrostatic analysis

    2011

    1 cites
  68. Decoding BDQ: Structural features, mechanistic action, and anti-TB Efficacy- A review

    2026

    View DOI
    0 cites
  69. Docking-Based Design, Synthesis, and Antioxidant Evaluation of Fluoxetine-Isatin Schiff Base Hybrid as Multitarget-Directed Ligand for Alzheimer’s Disease

    2026

    View DOI
    0 cites
  70. Breaking Barriers: Latest Frontiers in GPCR Structural Analysis

    2026

    View DOI
    0 cites
  71. Designing and computational studies of Novel 5-Fluorouracil hybrids as thymidylate synthase inhibitors for targeting non small cell lung cancer

    2025

    View DOI
    0 cites
  72. PyDescriptorC*: A Descriptor Calculation Tool for Decoding Chirality Cliffs and Revealing Hidden Patterns in Drug Discovery

    2025

    View DOI
    0 cites
  73. Author Correction: Multi-target in-silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors

    2024

    View DOI
    0 cites
  74. RP-HPLC Method Development and Validation of Rivaroxaban in Pharmaceutical Tablet Dosage Form

    2024

    View DOI
    0 cites
  75. Modular Synthesis of Pyridazinone Hybrid in Peg-400 as Cox-1/Cox-2 Inhibitor and Their Antioxidant Study

    2024

    View DOI
    0 cites
  76. Design, Synthesis, in Vitro and Molecular Docking-Dynamics Studies of 5-(Diethylamino)-2-Formylphenyl Naphthalene-2-Sulfonate Based Thiosemicarbazones as Potent Anti-Alzheimer Agents

    2024

    View DOI
    0 cites
  77. Mechanistic QSAR analysis to predict the binding affinity of diverse heterocycles as selective cannabinoid 2 receptor inhibitor

    2023

    View DOI
    0 cites
  78. QSAR modeling approaches to identify a novel ACE2 inhibitor that selectively bind with the C and N terminals of the ectodomain

    2023

    View DOI
    0 cites
  79. Pharmacognosy, phytochemistry, pharmacology and clinical application of Ginkgo biloba

    2021

    View DOI
    0 cites
  80. A Comprehensive Review on- Plant, Animal And Micoalgea as a alternative aspect for the Production of the Biodiesel

    2021

    0 cites
  81. In silico and experimental identification of non ulcerogenic antiinflammatory agents: 3-Thio substituted-4,5-diaryl-4 H -1,2,4-triazoles

    2014

    0 cites
  82. Presuming the Probable Anti-inflammatory Mechanism of Arganins derivatives and Ursolic Acid: Plant Derived Pentacyclic Triterpenoids, Using MOE Molecular Docking and POM Virtual Screening

    2014

    0 cites
  83. A review on Biologically Active Mercapto 1,3,4-Oxadiazole-2-thiol Derivatives

    2012

    0 cites
  84. Experimental-Computational Evaluation of Antimicrobial Activity of Some β-Lactams: Advantages and limitations

    2011

    0 cites
  85. Investigating the interactions of FCS-304 and other Monoamine Oxidase (MAO) A Inhibitors Using Molecular Docking

    2011

    0 cites